ClinicalTrials.gg
CompletedNCT04718870PELISTADUpdated Sep 15, 2025Results posted

Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis

A Phase 4 interventional study of Dupilumab SAR231893 in Dermatitis Atopic, sponsored by Sanofi. Completed at 3 sites in 2 countries. Open to participants aged 6 Years to 11 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-15.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
41
Allocation
Non-randomized
Ages
6 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing dupilumab in Dermatitis, Atopic — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Dermatitis, Atopic.

Enrollment
35th of 50
41 · median 75
Started
2021
with 4 others
Phase 4
24 of 50
4 open now
Registered
31st of 50
by date
Lead sponsor
10 of 50
Sanofi

Among the 50 studies testing dupilumab in Dermatitis, Atopic, this one is the 35th largest by enrollment, is one of 5 that started in 2021, is one of 24 in phase 4, and was the 31st registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 50 studies testing dupilumab in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 6 Years to 11 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing dupilumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

Primary Objective:

- Evaluate changes in skin barrier function with transepidermal water loss (TEWL) assessed after skin tape stripping (STS) in predefined lesional skin in pediatric participants with moderate to severe atopic dermatitis (AD) treated with dupilumab.

Secondary Objectives:

  • Evaluate changes in skin barrier function with TEWL assessed after STS in predefined lesional and non-lesional skin in pediatric participants with moderate to severe AD treated with dupilumab in reference to normal skin of healthy volunteers.
  • Evaluate time course of change in skin barrier function with TEWL assessed before and after STS in predefined lesional and non-lesional skin in pediatric participants with moderate to severe AD during dupilumab treatment phase and follow-up period in reference to normal skin of healthy volunteers.
Read the detailed description

Total study duration including screening and follow-up was 32 weeks.

03

Conditions studied

  • Dermatitis Atopic

Browse trials for

04

Who can participate

Ages eligible
6 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be between >=6 to \<12 years of age (inclusive), at the time of signing the
  • 15 kg \<= body weight \<60 kg.

Atopic dermatitis participants:

  • Male or female pediatric participants.
  • Participants with AD diagnosis according to Hanifin and Rajka criteria at least 1 year before screening.
  • Investigator Global Assessment (IGA) score of >=3 (for US participants) or IGA >=4 (for EU participants) at screening (on the 0-4 scale) depending on approved label indication in the country.
  • Participants with moderate to severe AD those were eligible to be treated with dupilumab according to product label.
  • Participants with AD must have had active lesions on the upper limbs or lower limbs (including trunk, if needed), with severity for lesion erythema or edema/papulation >=2 at screening on the 0-3 scale of the Individual Signs Score.
  • Participants should have had a non-lesional (normal looking) skin area 4 centimeter (cm) from the edge of the lesional area. If unable to identify non-lesional skin 4 cm from the lesional area, it was acceptable to identify normal looking skin as close to the lesion as possible.

Healthy volunteers:

- Age and gender matched (match on age ±2 years) to a selected AD participant by study site.

Exclusion criteria

Exclusion criteria:

  • Previous treatment with dupilumab within 6 months prior to screening.
  • Skin conditions other than AD that can confound assessments in the area of TEWL assessments in the opinion of the Investigator (i.e., skin atrophy, ichthyosis, tinea infection, contact dermatitis).
  • Cracked, crusted, oozing, or bleeding AD lesions in the designated lesional assessment area leaving insufficient skin that was adequate for TEWL assessments.
  • to the active substance or to any of the of dupilumab.
  • Ocular disorder that in the opinion of the Investigator could adversely affect the individual's risk for study participation. Examples include -but are not limited to- individuals with a history of active cases of herpes keratitis; Sjogren's syndrome, keratoconjunctivitis sicca, or individuals with ocular conditions that require the use of ocular or cyclosporine.
  • Healthy volunteers with a personal history of an atopic condition.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Atopic Dermatitis Participants

    Pediatric participants with moderate-to-severe atopic dermatitis (AD) and with baseline body weight more than or equal to (\>=) 15 kilograms (kg) and less than (\<) 30 kg received a subcutaneous (SC) loading dose of dupilumab 600 milligrams (mg) (2 injections of dupilumab 300 mg) on Day 1 (Week 0) followed by dupilumab 300 mg SC injection every 4 weeks (Q4W), from Week 4 to Week 12. Pediatric participants with body weight \>=30 kg and \<60 kg received SC loading dose of dupilumab 400 mg (2 injections of dupilumab 200 mg) on Day 1 (Week 0), followed by dupilumab 200 mg SC injection every 2 weeks (Q2W), from Week 2 to Week 14.

    Drug: Dupilumab SAR231893

  • No intervention
    Healthy Volunteers

    Healthy volunteers with age, gender, location of targeted skin lesion area and study site matched to selected AD participants, received no treatment, but were monitored in a similar way as AD participants.

Interventions

  • Pharmaceutical form: solution for injection Route of administration: subcutaneous (SC)

    Also known as: REGN668

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Transepidermal Water Loss (TEWL) After 5 Skin Tape Stripping (STS) on Lesional Skin (LS) in AD Participants at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize skin barrier function (SBF). TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. Lesional skin (LS) areas for TEWL assessment and STS was identified at Baseline ('predefined skin area'). Within the predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on the first spot. Percent Change from Baseline at Week 16 in TEWL after 5 STS on LS (first spot) in AD participants were reported in this outcome measure (OM).

    Time frame: Baseline, Week 16

Secondary outcomes

  1. Percent Change From Baseline in TEWL After 20 STS on Lesional Skin in AD Participants at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The LS areas for TEWL assessment and STS were identified at Baseline (predefined skin area). Within the predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 20 STS on LS (first spot) in AD participants were reported in this OM.

    Time frame: Baseline, Week 16

  2. Absolute Change From Baseline in TEWL After 20 STS on Lesional Skin in AD Participants at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that was used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from Baseline at Week 16 in TEWL after 20 STS on LS (first spot) in AD participants were reported in this OM

    Time frame: Baseline, Week 16

  3. Percent Change From Baseline in TEWL After 20 STS on Non-lesional Skin (Non-LS) in AD Participants at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from Baseline at Week 16 in TEWL after 20 STS on non-LS (first spot) in AD participants were reported in this OM.

    Time frame: Baseline, Week 16

  4. Absolute Change From Baseline in TEWL After 20 STS on Non-lesional Skin in AD Participants at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on the first spot. Absolute change from baseline at Week 16 in TEWL after 20 STS on non-LS (first spot) in AD participants were reported in this OM.

    Time frame: Baseline, Week 16

  5. Percent Change From Baseline in TEWL After 20 STS on Normal Skin in Healthy Volunteers at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 20 STS on normal skin (first spot) in healthy volunteers were reported in this OM.

    Time frame: Baseline, Week 16

  6. Absolute Change From Baseline in TEWL After 20 STS on Normal Skin in Healthy Volunteers at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from baseline at Week 16 in TEWL after 20 STS on normal skin (first spot) in healthy volunteers were reported in this OM.

    Time frame: Baseline, Week 16

  7. Percent Change From Baseline in TEWL After 15 STS on Lesional Skin in AD Participants at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS and non-LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 15 STS on LS (first spot) in AD participants were reported in this OM.

    Time frame: Baseline, Week 16

  8. Absolute Change From Baseline in TEWL After 15 STS on Lesional Skin in AD Participants at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from baseline at Week 16 in TEWL after 15 STS on LS (first spot) in AD participants were reported in this OM.

    Time frame: Baseline, Week 16

  9. Percent Change From Baseline in TEWL After 15 STS on Non-lesional Skin in AD Participants at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 15 STS on non-LS (first spot) in AD participants were reported in this OM.

    Time frame: Baseline, Week 16

  10. Absolute Change From Baseline in TEWL After 15 STS on Non-lesional Skin in AD Participants at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from baseline at Week 16 in TEWL after 15 STS on non-LS (first spot) in AD participants were reported in this OM.

    Time frame: Baseline, Week 16

  11. Percent Change From Baseline in TEWL After 15 STS on Normal Skin in Healthy Volunteers at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 15 STS on normal skin (first spot) in healthy volunteers were reported in this OM.

    Time frame: Baseline, Week 16

  12. Absolute Change From Baseline in TEWL After 15 STS on Normal Skin in Healthy Volunteers at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from baseline at Week 16 in TEWL after 15 STS on normal skin (first spot) in healthy volunteers were reported in this OM.

    Time frame: Baseline, Week 16

  13. Percent Change From Baseline in TEWL After 10 STS on Lesional Skin in AD Participants at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 10 STS on LS (first spot) in AD participants were reported in this OM.

    Time frame: Baseline, Week 16

  14. Absolute Change From Baseline in TEWL After 10 STS on Lesional Skin in AD Participants at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from baseline at Week 16 in TEWL after 10 STS on LS (first spot) in AD participants were reported in this OM.

    Time frame: Baseline, Week 16

  15. Percent Change From Baseline in TEWL After 10 STS on Non-lesional Skin in AD Participants at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 10 STS on non-LS (first spot) in AD participants were reported in this OM.

    Time frame: Baseline, Week 16

  16. Absolute Change From Baseline in TEWL After 10 STS on Non-lesional Skin in AD Participants at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from baseline at Week 16 in TEWL after 10 STS on non-LS (first spot) in AD participants were reported in this OM.

    Time frame: Baseline, Week 16

  17. Percent Change From Baseline in TEWL After 10 STS on Normal Skin in Healthy Volunteers at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 10 STS on normal skin (first spot) in healthy volunteers were reported in this OM.

    Time frame: Baseline, Week 16

  18. Absolute Change From Baseline in TEWL After 10 STS on Normal Skin in Healthy Volunteers at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from baseline at Week 16 in TEWL after 10 STS on normal skin (first spot) in healthy volunteers were reported in this OM.

    Time frame: Baseline, Week 16

  19. Percent Change From Baseline in TEWL After 5 STS on Non-lesional Skin in AD Participants at Week16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 5 STS on non-LS (first spot) in AD participants were reported in this OM.

    Time frame: Baseline, Week 16

  20. Absolute Change From Baseline in TEWL After 5 STS on Non-lesional Skin in AD Participants at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from baseline at Week 16 in TEWL after 5 STS on non-LS (first spot) in AD participants were reported in this OM.

    Time frame: Baseline, Week 16

  21. Percent Change From Baseline in TEWL After 5 STS on Normal Skin in Healthy Volunteers at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 5 STS on normal skin (first spot) in healthy volunteers were reported in this OM.

    Time frame: Baseline, Week 16

  22. Absolute Change From Baseline in TEWL After 5 STS on Normal Skin in Healthy Volunteers at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from baseline at Week 16 in TEWL after 5 STS on normal skin (first spot) in healthy volunteers were reported in this OM.

    Time frame: Baseline, Week 16

  23. Percent Change From Baseline in TEWL Before STS on Lesional Skin in AD Participants at Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. LS areas for TEWL assessment were identified at baseline ('predefined skin area'). Within predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS on pre-defined LS areas at specified time points. At each visit, before STS, all three spots were assessed. Percent change from Baseline at specified time points in TEWL before STS on LS (at each spot) in AD participants were reported in this OM.

    Time frame: Baseline, Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197

  24. Absolute Change From Baseline in TEWL Before STS on Lesional Skin in AD Participants at Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197

    TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. LS areas for TEWL assessment were identified at baseline (predefined skin area). Within predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS on pre-defined LS areas at specified time points. At each visit, before STS, all three spots were assessed. Absolute change from baseline at specified time points in TEWL before STS on LS (at each spot) in AD participants were reported in this OM.

    Time frame: Baseline, Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197

  25. Percent Change From Baseline in TEWL Before STS on Non-lesional Skin in AD Participants at Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. Non-LS areas for TEWL assessment were identified at baseline (predefined skin area). Within predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS on pre-defined non-LS areas at specified time points. At each visit, before STS, all three spots were assessed. Percent change from baseline at specified time points in TEWL before STS on non-LS (at each spot) in AD participants were reported in this OM.

    Time frame: Baseline, Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197

  26. Absolute Change From Baseline in TEWL Before STS on Non-lesional Skin in AD Participants at Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197

    TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. Non-LS areas for TEWL assessment were identified at baseline (predefined skin area). Within predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS on pre-defined non-LS areas at specified time points. At each visit, before STS, all three spots were assessed. Absolute change from baseline at specified time points in TEWL before STS on non-LS (at each spot) in AD participants were reported in this OM.

    Time frame: Baseline, Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197

  27. Percent Change From Baseline in TEWL Before STS on Normal Skin in Healthy Volunteers at Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197

    TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. Normal skin areas for TEWL assessment were identified at baseline (predefined skin area). Within predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS on pre-defined normal skin areas at specified time points. At each visit, before STS, all three spots were assessed. Percent change from Baseline at specified time points in TEWL before STS on normal skin (at each spot) in healthy volunteers were reported in this OM.

    Time frame: Baseline, Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197

  28. Absolute Change From Baseline in TEWL Before STS on Normal Skin in Healthy Volunteers at Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197

    TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. Normal skin areas for TEWL assessment were identified at baseline (predefined skin area). Within predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS on pre-defined normal skin areas at specified time points. At each visit, before STS, all three spots were assessed. Absolute change from baseline at specified time points in TEWL before STS on normal skin (at each spot) in healthy volunteers were reported in this OM.

    Time frame: Baseline, Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197

  29. Percent Change From Baseline in Area Under the Curve (AUC) of TEWL on Lesional Skin in AD Participants at Days 57, 113 and 197

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. TEWL AUC done over defined number of STS was used to reflect the overall integrity of the stratum corneum. LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. TEWL AUC was a composite measure before and after 5, 10, 15 and 20 STS at each specified time point. AUC of TEWL: calculated for each visit using trapezoidal method. STS assessment at baseline (Week 0, Day 1), Days 57, 113 and 197 was conducted on first spot. Percent change from baseline at specified time points in TEWL AUC (first spot) in AD participants were reported in this OM.

    Time frame: Baseline, Days 57, 113 and 197

  30. Absolute Change From Baseline in AUC of TEWL on Lesional Skin in AD Participants at Days 57, 113 and 197

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum to characterize SBF. TEWL combined with STS measures SBF. TEWL AUC done over defined number of STS (nsts) used to reflect the overall integrity of stratum corneum. LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. TEWL AUC was a composite measure before and after 5, 10, 15 and 20 STS at each specified time point. AUC of TEWL: calculated for each visit using trapezoidal method. STS assessment at baseline (Week 0, Day 1), Days 57, 113 and 197 was conducted on first spot. Absolute change from baseline at specified time points in TEWL AUC (first spot) in AD participants reported in this OM.

    Time frame: Baseline, Days 57, 113 and 197

  31. Percent Change From Baseline in AUC of TEWL on Non-lesional Skin in AD Participants at Days 57, 113 and 197

    TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum used to characterize SBF. TEWL combined with STS measures SBF. TEWL AUC done over defined number of STS reflect the overall integrity of the stratum corneum. Non-LS areas for TEWL assessment \& STS were identified at baseline (predefined skin area). Within predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL measured prior to STS \& after 5, 10, 15 \& 20 STS on pre-defined non-LS areas at specified time points. TEWL AUC was a composite measure before \& after 5, 10, 15 \&20 STS at each specified time point. AUC of TEWL: calculated for each visit using trapezoidal method. STS assessment at baseline (Week 0, Day 1), Days 57, 113 \& 197 was conducted on first spot. Percent change from baseline at specified time points in TEWL AUC (first spot) in AD participants were reported in this OM.

    Time frame: Baseline, Days 57, 113 and 197

  32. Absolute Change From Baseline in AUC of TEWL on Non-lesional Skin in AD Participants at Days 57, 113 and 197

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum to characterize SBF. TEWL combined with STS measures SBF. TEWL AUC done over defined number of STS used to reflect the overall integrity of stratum corneum. Non-LS areas for TEWL assessment and STS were identified at baseline(predefined skin area). Within predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10,15 and 20 STS on pre-defined non-LS areas at specified time points. TEWL AUC was a composite measure before and after 5, 10, 15 and 20 STS at each specified time point. AUC of TEWL: calculated for each visit using trapezoidal method. STS assessment at baseline(Week 0, Day 1), Days 57, 113 and 197 was conducted on first spot. Absolute change from baseline at specified time points in TEWL AUC (first spot) in AD participants reported in this OM.

    Time frame: Baseline, Days 57, 113 and 197

  33. Percent Change From Baseline in AUC of TEWL on Normal Skin in Healthy Volunteers at Days 57, 113 and 197

    TEWL: noninvasive in vivo measurement of water loss across stratum corneum to characterize SBF. TEWL combined with STS measures SBF. TEWL AUC done over a defined number of STS used to reflect the overall integrity of the stratum corneum. Normal skin areas for TEWL assessment \& STS were identified at baseline(predefined skin area). Within predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL measured prior to STS \& after 5, 10,15 \& 20 STS on pre-defined normal skin areas at specified time points. TEWL AUC: composite measure before \& after 5, 10, 15\& 20 STS at each specified time point. AUC of TEWL: calculated for each visit using trapezoidal method. STS assessment at baseline (Week 0, Day 1), Days 57, 113 \& 197 conducted on first spot. Percent Change from baseline at specified time points in TEWL AUC (first spot) in healthy volunteers reported in this OM.

    Time frame: Baseline, Days 57, 113 and 197

  34. Absolute Change From Baseline in AUC of TEWL on Normal Skin in Healthy Volunteers at Days 57, 113 and 197

    TEWL: noninvasive in vivo measurement of water loss across stratum corneum to characterize SBF. TEWL combined with STS measures SBF. TEWL AUC done over defined number of STS used to reflect the overall integrity of stratum corneum. Normal skin areas for TEWL assessment and STS identified at baseline(predefined skin area). Within predefined Normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL measured prior to STS and after 5, 10,15 and 20 STS on pre-defined Normal skin areas at specified time points. TEWL AUC was a composite measure before and after 5, 10,15 and 20 STS at each specified time point. AUC of TEWL: calculated for each visit using trapezoidal method. STS assessment at baseline (Week 0, Day 1), Days 57, 113 and 197 conducted on first spot. Percent change from baseline at specified time points in TEWL AUC (first spot) in healthy volunteers reported in this OM.

    Time frame: Baseline, Days 57, 113 and 197

  35. Percent Change From Baseline in TEWL After 5, 10, 15 and 20 STS on Lesional Skin in AD Participants at Days 57, 113 and 197

    TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of skin are peeled away using adhesive discs. LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL: measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. STS assessment at baseline (Week 0, Day 1), Day 57, 113 and 197 were conducted on first spot. Percent change from baseline at specified time points in TEWL after STS on LS (first spot) in AD participant were reported in this OM.

    Time frame: Baseline, Days 57, 113 and 197

  36. Absolute Change From Baseline in TEWL After 5, 10, 15 and 20 STS on Lesional Skin in AD Participants at Days 57, 113 and 197

    TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of skin are peeled away using adhesive discs. LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL: measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. STS assessment at baseline (Week 0, Day 1), Day 57, 113 and 197 was conducted on first spot. Absolute change from baseline at specified time points in TEWL after STS on LS (first spot) in AD participants were reported in this OM.

    Time frame: Baseline, Days 57, 113 and 197

  37. Percent Change From Baseline in TEWL After 5, 10, 15 and 20 STS on Non-lesional Skin in AD Participants at Days 57, 113 and 197

    TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, uppermost layers of skin are peeled away using adhesive discs. Non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL: measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at baseline (Week 0, Day 1), Day 57, 113and 197 was conducted on first spot. Percent change from baseline at specified time points in TEWL after STS on non-LS (first spot) in AD participants were reported in this OM.

    Time frame: Baseline, Days 57, 113 and 197

  38. Secondary: Absolute Change From Baseline in TEWL After 5, 10, 15 and 20 STS on Non-lesional Skin in AD Participants at Days 57, 113 and 197

    TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, uppermost layers of skin are peeled away using adhesive discs. Non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL: measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at baseline (Week 0, Day 1), Day 57, 113 and 197 was conducted on the first spot. Absolute change from baseline at specified time points in TEWL after STS on non-LS (first spot) in AD participants were reported in this OM.

    Time frame: Baseline, Days 57, 113 and 197

  39. Percent Change From Baseline in TEWL After 5, 10, 15 and 20 STS on Normal Skin in Healthy Volunteers at Days 57, 113 and 197

    TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, uppermost layers of skin are peeled away using adhesive discs. Normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at baseline (Week 0, Day 1), Day 57, 113 and 197 was conducted on first spot. Percent change from baseline at specified time points in TEWL after STS on normal skin (first spot) in healthy volunteers were reported in this OM.

    Time frame: Baseline, Days 57, 113 and 197

  40. Absolute Change From Baseline in TEWL After 5, 10, 15 and 20 STS on Normal Skin in Healthy Volunteers at Days 57, 113 and 197

    TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, uppermost layers of skin are peeled away using adhesive discs. Normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at baseline (Week 0, Day 1), Day 57, 113 and 197 were conducted on first spot. Absolute change from baseline at specified time points in TEWL after STS on normal skin (first spot) in healthy volunteers were reported in this OM.

    Time frame: Baseline, Days 57, 113 and 197

07

Results

Posted Oct 17, 2023

Participant flow

Study was conducted at 3 active sites in the United States and United Kingdom. A total of 43 participants were screened between 19 Feb 2021 and 12 May 2022, out of which 41 were enrolled and 2 were screen failures due to not meeting inclusion criteria.

Participant flow — Overall Study
MilestoneHealthy VolunteersAtopic Dermatitis Participants
Started1823
Completed1823
Not completed00

Outcome measures

PrimaryPercent Change From Baseline in Transepidermal Water Loss (TEWL) After 5 Skin Tape Stripping (STS) on Lesional Skin (LS) in AD Participants at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize skin barrier function (SBF). TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. Lesional skin (LS) areas for TEWL assessment and STS was identified at Baseline ('predefined skin area'). Within the predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on the first spot. Percent Change from Baseline at Week 16 in TEWL after 5 STS on LS (first spot) in AD participants were reported in this outcome measure (OM).

Time frame:
Baseline, Week 16
Reported as:
Mean · percent change
Percent Change From Baseline in Transepidermal Water Loss (TEWL) After 5 Skin Tape Stripping (STS) on Lesional Skin (LS) in AD Participants at Week 16
percent changeAtopic Dermatitis Participants
Percent Change From Baseline in Transepidermal Water Loss (TEWL) After 5 Skin Tape Stripping (STS) on Lesional Skin (LS) in AD Participants at Week 16-38.5633 ± 27.1211
SecondaryPercent Change From Baseline in TEWL After 20 STS on Lesional Skin in AD Participants at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The LS areas for TEWL assessment and STS were identified at Baseline (predefined skin area). Within the predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 20 STS on LS (first spot) in AD participants were reported in this OM.

Time frame:
Baseline, Week 16
Reported as:
Mean · percent change
Percent Change From Baseline in TEWL After 20 STS on Lesional Skin in AD Participants at Week 16
percent changeAtopic Dermatitis Participants
Percent Change From Baseline in TEWL After 20 STS on Lesional Skin in AD Participants at Week 16-33.1336 ± 28.1613
SecondaryAbsolute Change From Baseline in TEWL After 20 STS on Lesional Skin in AD Participants at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that was used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from Baseline at Week 16 in TEWL after 20 STS on LS (first spot) in AD participants were reported in this OM

Time frame:
Baseline, Week 16
Reported as:
Mean · grams per square meter per hour
Absolute Change From Baseline in TEWL After 20 STS on Lesional Skin in AD Participants at Week 16
grams per square meter per hourAtopic Dermatitis Participants
Absolute Change From Baseline in TEWL After 20 STS on Lesional Skin in AD Participants at Week 16-35.6671 ± 31.2267
SecondaryPercent Change From Baseline in TEWL After 20 STS on Non-lesional Skin (Non-LS) in AD Participants at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from Baseline at Week 16 in TEWL after 20 STS on non-LS (first spot) in AD participants were reported in this OM.

Time frame:
Baseline, Week 16
Reported as:
Mean · percent change
Percent Change From Baseline in TEWL After 20 STS on Non-lesional Skin (Non-LS) in AD Participants at Week 16
percent changeAtopic Dermatitis Participants
Percent Change From Baseline in TEWL After 20 STS on Non-lesional Skin (Non-LS) in AD Participants at Week 16-6.1452 ± 67.9496
SecondaryAbsolute Change From Baseline in TEWL After 20 STS on Non-lesional Skin in AD Participants at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on the first spot. Absolute change from baseline at Week 16 in TEWL after 20 STS on non-LS (first spot) in AD participants were reported in this OM.

Time frame:
Baseline, Week 16
Reported as:
Mean · grams per square meter per hour
Absolute Change From Baseline in TEWL After 20 STS on Non-lesional Skin in AD Participants at Week 16
grams per square meter per hourAtopic Dermatitis Participants
Absolute Change From Baseline in TEWL After 20 STS on Non-lesional Skin in AD Participants at Week 16-13.6682 ± 33.3065
SecondaryPercent Change From Baseline in TEWL After 20 STS on Normal Skin in Healthy Volunteers at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 20 STS on normal skin (first spot) in healthy volunteers were reported in this OM.

Time frame:
Baseline, Week 16
Reported as:
Mean · percent change
Percent Change From Baseline in TEWL After 20 STS on Normal Skin in Healthy Volunteers at Week 16
percent changeHealthy Volunteers
Percent Change From Baseline in TEWL After 20 STS on Normal Skin in Healthy Volunteers at Week 1613.2578 ± 64.3880
SecondaryAbsolute Change From Baseline in TEWL After 20 STS on Normal Skin in Healthy Volunteers at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from baseline at Week 16 in TEWL after 20 STS on normal skin (first spot) in healthy volunteers were reported in this OM.

Time frame:
Baseline, Week 16
Reported as:
Mean · grams per square meter per hour
Absolute Change From Baseline in TEWL After 20 STS on Normal Skin in Healthy Volunteers at Week 16
grams per square meter per hourHealthy Volunteers
Absolute Change From Baseline in TEWL After 20 STS on Normal Skin in Healthy Volunteers at Week 165.9327 ± 32.0123
SecondaryPercent Change From Baseline in TEWL After 15 STS on Lesional Skin in AD Participants at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS and non-LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 15 STS on LS (first spot) in AD participants were reported in this OM.

Time frame:
Baseline, Week 16
Reported as:
Mean · percent change
Percent Change From Baseline in TEWL After 15 STS on Lesional Skin in AD Participants at Week 16
percent changeAtopic Dermatitis Participants
Percent Change From Baseline in TEWL After 15 STS on Lesional Skin in AD Participants at Week 16-33.3119 ± 32.7125
SecondaryAbsolute Change From Baseline in TEWL After 15 STS on Lesional Skin in AD Participants at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from baseline at Week 16 in TEWL after 15 STS on LS (first spot) in AD participants were reported in this OM.

Time frame:
Baseline, Week 16
Reported as:
Mean · grams per square meter per hour
Absolute Change From Baseline in TEWL After 15 STS on Lesional Skin in AD Participants at Week 16
grams per square meter per hourAtopic Dermatitis Participants
Absolute Change From Baseline in TEWL After 15 STS on Lesional Skin in AD Participants at Week 16-33.4028 ± 31.1957
SecondaryPercent Change From Baseline in TEWL After 15 STS on Non-lesional Skin in AD Participants at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 15 STS on non-LS (first spot) in AD participants were reported in this OM.

Time frame:
Baseline, Week 16
Reported as:
Mean · percent change
Percent Change From Baseline in TEWL After 15 STS on Non-lesional Skin in AD Participants at Week 16
percent changeAtopic Dermatitis Participants
Percent Change From Baseline in TEWL After 15 STS on Non-lesional Skin in AD Participants at Week 16-7.6067 ± 54.7945
SecondaryAbsolute Change From Baseline in TEWL After 15 STS on Non-lesional Skin in AD Participants at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from baseline at Week 16 in TEWL after 15 STS on non-LS (first spot) in AD participants were reported in this OM.

Time frame:
Baseline, Week 16
Reported as:
Mean · grams per square meter per hour
Absolute Change From Baseline in TEWL After 15 STS on Non-lesional Skin in AD Participants at Week 16
grams per square meter per hourAtopic Dermatitis Participants
Absolute Change From Baseline in TEWL After 15 STS on Non-lesional Skin in AD Participants at Week 16-12.6576 ± 30.0412
SecondaryPercent Change From Baseline in TEWL After 15 STS on Normal Skin in Healthy Volunteers at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 15 STS on normal skin (first spot) in healthy volunteers were reported in this OM.

Time frame:
Baseline, Week 16
Reported as:
Mean · percent change
Percent Change From Baseline in TEWL After 15 STS on Normal Skin in Healthy Volunteers at Week 16
percent changeHealthy Volunteers
Percent Change From Baseline in TEWL After 15 STS on Normal Skin in Healthy Volunteers at Week 164.5364 ± 42.7525
SecondaryAbsolute Change From Baseline in TEWL After 15 STS on Normal Skin in Healthy Volunteers at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from baseline at Week 16 in TEWL after 15 STS on normal skin (first spot) in healthy volunteers were reported in this OM.

Time frame:
Baseline, Week 16
Reported as:
Mean · grams per square meter per hour
Absolute Change From Baseline in TEWL After 15 STS on Normal Skin in Healthy Volunteers at Week 16
grams per square meter per hourHealthy Volunteers
Absolute Change From Baseline in TEWL After 15 STS on Normal Skin in Healthy Volunteers at Week 160.1082 ± 17.5865
SecondaryPercent Change From Baseline in TEWL After 10 STS on Lesional Skin in AD Participants at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 10 STS on LS (first spot) in AD participants were reported in this OM.

Time frame:
Baseline, Week 16
Reported as:
Mean · percent change
Percent Change From Baseline in TEWL After 10 STS on Lesional Skin in AD Participants at Week 16
percent changeAtopic Dermatitis Participants
Percent Change From Baseline in TEWL After 10 STS on Lesional Skin in AD Participants at Week 16-34.7741 ± 31.0541
SecondaryAbsolute Change From Baseline in TEWL After 10 STS on Lesional Skin in AD Participants at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from baseline at Week 16 in TEWL after 10 STS on LS (first spot) in AD participants were reported in this OM.

Time frame:
Baseline, Week 16
Reported as:
Mean · grams per square meter per hour
Absolute Change From Baseline in TEWL After 10 STS on Lesional Skin in AD Participants at Week 16
grams per square meter per hourAtopic Dermatitis Participants
Absolute Change From Baseline in TEWL After 10 STS on Lesional Skin in AD Participants at Week 16-33.1024 ± 36.2286
SecondaryPercent Change From Baseline in TEWL After 10 STS on Non-lesional Skin in AD Participants at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 10 STS on non-LS (first spot) in AD participants were reported in this OM.

Time frame:
Baseline, Week 16
Reported as:
Mean · percent change
Percent Change From Baseline in TEWL After 10 STS on Non-lesional Skin in AD Participants at Week 16
percent changeAtopic Dermatitis Participants
Percent Change From Baseline in TEWL After 10 STS on Non-lesional Skin in AD Participants at Week 16-3.8193 ± 74.6263
SecondaryAbsolute Change From Baseline in TEWL After 10 STS on Non-lesional Skin in AD Participants at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from baseline at Week 16 in TEWL after 10 STS on non-LS (first spot) in AD participants were reported in this OM.

Time frame:
Baseline, Week 16
Reported as:
Mean · grams per square meter per hour
Absolute Change From Baseline in TEWL After 10 STS on Non-lesional Skin in AD Participants at Week 16
grams per square meter per hourAtopic Dermatitis Participants
Absolute Change From Baseline in TEWL After 10 STS on Non-lesional Skin in AD Participants at Week 16-10.9488 ± 31.1300
SecondaryPercent Change From Baseline in TEWL After 10 STS on Normal Skin in Healthy Volunteers at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 10 STS on normal skin (first spot) in healthy volunteers were reported in this OM.

Time frame:
Baseline, Week 16
Reported as:
Mean · percent change
Percent Change From Baseline in TEWL After 10 STS on Normal Skin in Healthy Volunteers at Week 16
percent changeHealthy Volunteers
Percent Change From Baseline in TEWL After 10 STS on Normal Skin in Healthy Volunteers at Week 160.7091 ± 25.0615
SecondaryAbsolute Change From Baseline in TEWL After 10 STS on Normal Skin in Healthy Volunteers at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from baseline at Week 16 in TEWL after 10 STS on normal skin (first spot) in healthy volunteers were reported in this OM.

Time frame:
Baseline, Week 16
Reported as:
Mean · grams per square meter per hour
Absolute Change From Baseline in TEWL After 10 STS on Normal Skin in Healthy Volunteers at Week 16
grams per square meter per hourHealthy Volunteers
Absolute Change From Baseline in TEWL After 10 STS on Normal Skin in Healthy Volunteers at Week 16-1.3482 ± 6.6778
SecondaryPercent Change From Baseline in TEWL After 5 STS on Non-lesional Skin in AD Participants at Week16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 5 STS on non-LS (first spot) in AD participants were reported in this OM.

Time frame:
Baseline, Week 16
Reported as:
Mean · percent change
Percent Change From Baseline in TEWL After 5 STS on Non-lesional Skin in AD Participants at Week16
percent changeAtopic Dermatitis Participants
Percent Change From Baseline in TEWL After 5 STS on Non-lesional Skin in AD Participants at Week16-4.8842 ± 70.5670
SecondaryAbsolute Change From Baseline in TEWL After 5 STS on Non-lesional Skin in AD Participants at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from baseline at Week 16 in TEWL after 5 STS on non-LS (first spot) in AD participants were reported in this OM.

Time frame:
Baseline, Week 16
Reported as:
Mean · grams per square meter per hour
Absolute Change From Baseline in TEWL After 5 STS on Non-lesional Skin in AD Participants at Week 16
grams per square meter per hourAtopic Dermatitis Participants
Absolute Change From Baseline in TEWL After 5 STS on Non-lesional Skin in AD Participants at Week 16-9.0771 ± 21.3022
SecondaryPercent Change From Baseline in TEWL After 5 STS on Normal Skin in Healthy Volunteers at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from baseline at Week 16 in TEWL after 5 STS on normal skin (first spot) in healthy volunteers were reported in this OM.

Time frame:
Baseline, Week 16
Reported as:
Mean · percent change
Percent Change From Baseline in TEWL After 5 STS on Normal Skin in Healthy Volunteers at Week 16
percent changeHealthy Volunteers
Percent Change From Baseline in TEWL After 5 STS on Normal Skin in Healthy Volunteers at Week 161.4464 ± 26.7257
SecondaryAbsolute Change From Baseline in TEWL After 5 STS on Normal Skin in Healthy Volunteers at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from baseline at Week 16 in TEWL after 5 STS on normal skin (first spot) in healthy volunteers were reported in this OM.

Time frame:
Baseline, Week 16
Reported as:
Mean · grams per square meter per hour
Absolute Change From Baseline in TEWL After 5 STS on Normal Skin in Healthy Volunteers at Week 16
grams per square meter per hourHealthy Volunteers
Absolute Change From Baseline in TEWL After 5 STS on Normal Skin in Healthy Volunteers at Week 16-1.0255 ± 4.3657
SecondaryPercent Change From Baseline in TEWL Before STS on Lesional Skin in AD Participants at Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. LS areas for TEWL assessment were identified at baseline ('predefined skin area'). Within predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS on pre-defined LS areas at specified time points. At each visit, before STS, all three spots were assessed. Percent change from Baseline at specified time points in TEWL before STS on LS (at each spot) in AD participants were reported in this OM.

Time frame:
Baseline, Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197
Reported as:
Mean · percent change
Percent Change From Baseline in TEWL Before STS on Lesional Skin in AD Participants at Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197
percent changeAtopic Dermatitis Participants
Day 8 - Spot 1-7.1596 ± 36.6637
Day 8 - Spot 2-6.3439 ± 33.8145
Day 8 - Spot 3-7.0747 ± 28.3554
Day 15 - Spot 1-15.3096 ± 45.6163
Day 15 - Spot 2-11.0740 ± 35.5483
Day 15 - Spot 3-8.1780 ± 44.9382
Day 22 - Spot 1-30.3070 ± 33.6643
Day 22 - Spot 2-29.1730 ± 31.7167
Day 22 - Spot 3-27.0015 ± 25.8528
Day 29 - Spot 1-37.8349 ± 24.7709
Day 29 - Spot 2-33.0139 ± 27.8560
Day 29 - Spot 3-32.7080 ± 28.8445
Day 43 - Spot 1-37.8675 ± 29.0275
Day 43 - Spot 2-36.1625 ± 28.9829
Day 43 - Spot 3-32.9996 ± 33.2028
Day 57 - Spot 1-38.2449 ± 40.0558
Day 57 - Spot 2-39.3104 ± 27.6888
Day 57 - Spot 3-35.8992 ± 27.9526
Day 85 - Spot 1-45.6060 ± 23.2839
Day 85 - Spot 2-40.8609 ± 30.8002
Day 85 - Spot 3-41.1371 ± 24.5842
Day 113 - Spot 1-36.0863 ± 33.7259
Day 113 - Spot 2-37.4815 ± 30.8507
Day 113 - Spot 3-32.3491 ± 29.2966
Day 155 - Spot 1-40.9536 ± 30.9966
Day 155 - Spot 2-20.8463 ± 50.6518
Day 155 - Spot 3-31.3185 ± 42.0614
Day 197 - Spot 1-35.2305 ± 45.8818
Day 197 - Spot 2-30.3358 ± 48.3028
Day 197 - Spot 3-36.5267 ± 37.7230
SecondaryAbsolute Change From Baseline in TEWL Before STS on Lesional Skin in AD Participants at Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197

TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. LS areas for TEWL assessment were identified at baseline (predefined skin area). Within predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS on pre-defined LS areas at specified time points. At each visit, before STS, all three spots were assessed. Absolute change from baseline at specified time points in TEWL before STS on LS (at each spot) in AD participants were reported in this OM.

Time frame:
Baseline, Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197
Reported as:
Mean · grams per square meter per hour
Absolute Change From Baseline in TEWL Before STS on Lesional Skin in AD Participants at Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197
grams per square meter per hourAtopic Dermatitis Participants
Day 8 - Spot 1-9.3486 ± 21.2256
Day 8 - Spot 2-6.0491 ± 17.5810
Day 8 - Spot 3-3.1965 ± 14.4640
Day 15 - Spot 1-15.4336 ± 25.0975
Day 15 - Spot 2-9.8073 ± 19.7385
Day 15 - Spot 3-7.6682 ± 21.9239
Day 22 - Spot 1-23.0157 ± 26.8847
Day 22 - Spot 2-20.7186 ± 23.4149
Day 22 - Spot 3-15.6557 ± 20.1212
Day 29 - Spot 1-23.9585 ± 21.7106
Day 29 - Spot 2-21.2010 ± 21.2593
Day 29 - Spot 3-17.9170 ± 19.7310
Day 43 - Spot 1-27.0535 ± 28.0249
Day 43 - Spot 2-24.5188 ± 25.6684
Day 43 - Spot 3-20.7018 ± 22.5936
Day 57 - Spot 1-25.1221 ± 27.0210
Day 57 - Spot 2-24.2358 ± 24.6028
Day 57 - Spot 3-20.3379 ± 20.3751
Day 85 - Spot 1-29.1917 ± 24.3114
Day 85 - Spot 2-24.4494 ± 24.2054
Day 85 - Spot 3-23.1056 ± 20.4692
Day 113 - Spot 1-24.6678 ± 27.8013
Day 113 - Spot 2-23.2878 ± 26.5670
Day 113 - Spot 3-17.9028 ± 22.2483
Day 155 - Spot 1-28.2564 ± 29.2212
Day 155 - Spot 2-18.7786 ± 31.4917
Day 155 - Spot 3-19.8921 ± 27.8520
Day 197 - Spot 1-27.4493 ± 33.7080
Day 197 - Spot 2-22.5607 ± 31.7696
Day 197 - Spot 3-22.0860 ± 27.1286
SecondaryPercent Change From Baseline in TEWL Before STS on Non-lesional Skin in AD Participants at Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. Non-LS areas for TEWL assessment were identified at baseline (predefined skin area). Within predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS on pre-defined non-LS areas at specified time points. At each visit, before STS, all three spots were assessed. Percent change from baseline at specified time points in TEWL before STS on non-LS (at each spot) in AD participants were reported in this OM.

Time frame:
Baseline, Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197
Reported as:
Mean · percent change
Percent Change From Baseline in TEWL Before STS on Non-lesional Skin in AD Participants at Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197
percent changeAtopic Dermatitis Participants
Day 8 - Spot 141.0825 ± 91.3744
Day 8 - Spot 213.5236 ± 49.3733
Day 8 - Spot 39.7943 ± 43.9272
Day 15 - Spot 119.0612 ± 58.1703
Day 15 - Spot 29.6866 ± 52.6831
Day 15 - Spot 313.2574 ± 55.8095
Day 22 - Spot 1-3.9277 ± 35.9880
Day 22 - Spot 28.9306 ± 70.2617
Day 22 - Spot 30.4973 ± 49.5636
Day 29 - Spot 1-8.9585 ± 39.0443
Day 29 - Spot 2-10.5728 ± 35.2672
Day 29 - Spot 3-13.0407 ± 44.5264
Day 43 - Spot 1-15.6919 ± 29.7995
Day 43 - Spot 2-21.6885 ± 30.1255
Day 43 - Spot 3-16.2025 ± 42.7984
Day 57 - Spot 1-24.5008 ± 26.9801
Day 57 - Spot 2-27.6040 ± 23.0969
Day 57 - Spot 3-25.7321 ± 33.1310
Day 85 - Spot 1-21.9316 ± 34.3620
Day 85 - Spot 2-16.7008 ± 62.4384
Day 85 - Spot 3-29.2721 ± 40.0673
Day 113 - Spot 1-20.4359 ± 42.6948
Day 113 - Spot 2-23.1303 ± 41.2717
Day 113 - Spot 3-27.4981 ± 33.5326
Day 155 - Spot 1-6.7535 ± 73.4261
Day 155 - Spot 2-16.3903 ± 41.9864
Day 155 - Spot 3-19.3970 ± 46.5302
Day 197 - Spot 1-23.3812 ± 39.5978
Day 197 - Spot 2-27.3104 ± 32.8267
Day 197 - Spot 3-22.1813 ± 40.5124
SecondaryAbsolute Change From Baseline in TEWL Before STS on Non-lesional Skin in AD Participants at Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197

TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. Non-LS areas for TEWL assessment were identified at baseline (predefined skin area). Within predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS on pre-defined non-LS areas at specified time points. At each visit, before STS, all three spots were assessed. Absolute change from baseline at specified time points in TEWL before STS on non-LS (at each spot) in AD participants were reported in this OM.

Time frame:
Baseline, Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197
Reported as:
Mean · grams per square meter per hour
Absolute Change From Baseline in TEWL Before STS on Non-lesional Skin in AD Participants at Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197
grams per square meter per hourAtopic Dermatitis Participants
Day 8 - Spot 14.1752 ± 14.1047
Day 8 - Spot 2-0.0248 ± 11.8585
Day 8 - Spot 3-0.3413 ± 9.8571
Day 15 - Spot 10.4723 ± 9.7975
Day 15 - Spot 2-2.6176 ± 13.1001
Day 15 - Spot 3-1.0171 ± 11.3877
Day 22 - Spot 1-3.8162 ± 10.3046
Day 22 - Spot 2-3.5735 ± 16.4593
Day 22 - Spot 3-5.3314 ± 12.8392
Day 29 - Spot 1-5.3400 ± 10.8674
Day 29 - Spot 2-6.7411 ± 13.5999
Day 29 - Spot 3-9.5905 ± 14.0754
Day 43 - Spot 1-6.7424 ± 9.7834
Day 43 - Spot 2-8.8444 ± 12.4876
Day 43 - Spot 3-10.5600 ± 14.1984
Day 57 - Spot 1-8.2874 ± 8.5546
Day 57 - Spot 2-9.7772 ± 11.7879
Day 57 - Spot 3-11.9179 ± 13.1662
Day 85 - Spot 1-8.2272 ± 11.6158
Day 85 - Spot 2-7.6171 ± 16.1511
Day 85 - Spot 3-13.1811 ± 14.4647
Day 113 - Spot 1-8.0665 ± 11.9970
Day 113 - Spot 2-9.2906 ± 13.7202
Day 113 - Spot 3-11.2776 ± 12.9322
Day 155 - Spot 1-7.0229 ± 15.4066
Day 155 - Spot 2-7.0408 ± 12.8562
Day 155 - Spot 3-10.4414 ± 14.5146
Day 197 - Spot 1-8.9200 ± 11.3266
Day 197 - Spot 2-11.2953 ± 15.3452
Day 197 - Spot 3-11.1625 ± 16.2087
SecondaryPercent Change From Baseline in TEWL Before STS on Normal Skin in Healthy Volunteers at Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197

TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. Normal skin areas for TEWL assessment were identified at baseline (predefined skin area). Within predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS on pre-defined normal skin areas at specified time points. At each visit, before STS, all three spots were assessed. Percent change from Baseline at specified time points in TEWL before STS on normal skin (at each spot) in healthy volunteers were reported in this OM.

Time frame:
Baseline, Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197
Reported as:
Mean · percent change
Percent Change From Baseline in TEWL Before STS on Normal Skin in Healthy Volunteers at Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197
percent changeHealthy Volunteers
Day 8 - Spot 15.0103 ± 39.4170
Day 8 - Spot 2-8.7688 ± 20.5764
Day 8 - Spot 3-3.8203 ± 19.5160
Day 15 - Spot 11.9837 ± 27.7012
Day 15 - Spot 2-4.0758 ± 22.1886
Day 15 - Spot 3-1.7489 ± 21.1652
Day 22 - Spot 1-2.6655 ± 19.8558
Day 22 - Spot 27.5939 ± 22.7859
Day 22 - Spot 33.8603 ± 12.1068
Day 29 - Spot 1-1.7648 ± 21.4820
Day 29 - Spot 29.9969 ± 14.4219
Day 29 - Spot 38.4098 ± 15.2499
Day 43 - Spot 11.4115 ± 27.8012
Day 43 - Spot 22.9668 ± 30.1272
Day 43 - Spot 313.4093 ± 35.9985
Day 57 - Spot 17.6533 ± 24.0747
Day 57 - Spot 25.3384 ± 17.9065
Day 57 - Spot 312.6926 ± 24.7125
Day 85 - Spot 15.2021 ± 23.1397
Day 85 - Spot 20.7096 ± 19.5448
Day 85 - Spot 35.1021 ± 20.0690
Day 113 - Spot 12.6054 ± 26.2241
Day 113 - Spot 29.4234 ± 24.1533
Day 113 - Spot 317.0905 ± 16.4596
Day 155 - Spot 110.3105 ± 52.8138
Day 155 - Spot 211.2398 ± 22.7028
Day 155 - Spot 311.5842 ± 27.2298
Day 197 - Spot 13.3636 ± 26.9400
Day 197 - Spot 25.3772 ± 19.9583
Day 197 - Spot 312.0900 ± 24.8690
SecondaryAbsolute Change From Baseline in TEWL Before STS on Normal Skin in Healthy Volunteers at Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197

TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. Normal skin areas for TEWL assessment were identified at baseline (predefined skin area). Within predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS on pre-defined normal skin areas at specified time points. At each visit, before STS, all three spots were assessed. Absolute change from baseline at specified time points in TEWL before STS on normal skin (at each spot) in healthy volunteers were reported in this OM.

Time frame:
Baseline, Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197
Reported as:
Mean · grams per square meter per hour
Absolute Change From Baseline in TEWL Before STS on Normal Skin in Healthy Volunteers at Days 8, 15, 22, 29, 43, 57, 85, 113, 155 and 197
grams per square meter per hourHealthy Volunteers
Day 8 - Spot 1-0.2508 ± 4.8798
Day 8 - Spot 2-1.8215 ± 3.3907
Day 8 - Spot 3-0.7869 ± 2.9791
Day 15 - Spot 1-0.5786 ± 3.3947
Day 15 - Spot 2-1.0029 ± 3.4320
Day 15 - Spot 3-0.3829 ± 3.3925
Day 22 - Spot 1-0.7575 ± 3.2991
Day 22 - Spot 21.0233 ± 3.7207
Day 22 - Spot 30.6433 ± 2.0759
Day 29 - Spot 1-1.1631 ± 3.1429
Day 29 - Spot 20.8585 ± 1.8609
Day 29 - Spot 30.7938 ± 1.7624
Day 43 - Spot 1-1.0129 ± 4.0940
Day 43 - Spot 2-0.8357 ± 4.7103
Day 43 - Spot 30.7057 ± 5.1247
Day 57 - Spot 10.6308 ± 4.1304
Day 57 - Spot 20.2283 ± 2.6839
Day 57 - Spot 31.5142 ± 4.1943
Day 85 - Spot 10.0164 ± 3.2348
Day 85 - Spot 2-0.3221 ± 3.5460
Day 85 - Spot 30.2779 ± 3.8491
Day 113 - Spot 1-0.3791 ± 3.4231
Day 113 - Spot 20.4882 ± 2.5528
Day 113 - Spot 32.0527 ± 2.1762
Day 155 - Spot 1-0.9293 ± 6.5972
Day 155 - Spot 20.6880 ± 3.7653
Day 155 - Spot 30.4793 ± 4.5057
Day 197 - Spot 1-0.6153 ± 4.8187
Day 197 - Spot 2-0.0427 ± 3.6560
Day 197 - Spot 30.6747 ± 4.8536
SecondaryPercent Change From Baseline in Area Under the Curve (AUC) of TEWL on Lesional Skin in AD Participants at Days 57, 113 and 197

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. TEWL AUC done over defined number of STS was used to reflect the overall integrity of the stratum corneum. LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within the predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. TEWL AUC was a composite measure before and after 5, 10, 15 and 20 STS at each specified time point. AUC of TEWL: calculated for each visit using trapezoidal method. STS assessment at baseline (Week 0, Day 1), Days 57, 113 and 197 was conducted on first spot. Percent change from baseline at specified time points in TEWL AUC (first spot) in AD participants were reported in this OM.

Time frame:
Baseline, Days 57, 113 and 197
Reported as:
Mean · percent change
Percent Change From Baseline in Area Under the Curve (AUC) of TEWL on Lesional Skin in AD Participants at Days 57, 113 and 197
percent changeAtopic Dermatitis Participants
Day 57-38.2091 ± 25.6654
Day 113-34.0025 ± 29.1866
Day 197-40.0143 ± 26.9737
SecondaryAbsolute Change From Baseline in AUC of TEWL on Lesional Skin in AD Participants at Days 57, 113 and 197

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum to characterize SBF. TEWL combined with STS measures SBF. TEWL AUC done over defined number of STS (nsts) used to reflect the overall integrity of stratum corneum. LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. TEWL AUC was a composite measure before and after 5, 10, 15 and 20 STS at each specified time point. AUC of TEWL: calculated for each visit using trapezoidal method. STS assessment at baseline (Week 0, Day 1), Days 57, 113 and 197 was conducted on first spot. Absolute change from baseline at specified time points in TEWL AUC (first spot) in AD participants reported in this OM.

Time frame:
Baseline, Days 57, 113 and 197
Reported as:
Mean · nsts*grams per square meter per hour
Absolute Change From Baseline in AUC of TEWL on Lesional Skin in AD Participants at Days 57, 113 and 197
nsts*grams per square meter per hourAtopic Dermatitis Participants
Day 57-632.0224 ± 494.4981
Day 113-608.1875 ± 601.7999
Day 197-659.4033 ± 570.2425
SecondaryPercent Change From Baseline in AUC of TEWL on Non-lesional Skin in AD Participants at Days 57, 113 and 197

TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum used to characterize SBF. TEWL combined with STS measures SBF. TEWL AUC done over defined number of STS reflect the overall integrity of the stratum corneum. Non-LS areas for TEWL assessment \& STS were identified at baseline (predefined skin area). Within predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL measured prior to STS \& after 5, 10, 15 \& 20 STS on pre-defined non-LS areas at specified time points. TEWL AUC was a composite measure before \& after 5, 10, 15 \&20 STS at each specified time point. AUC of TEWL: calculated for each visit using trapezoidal method. STS assessment at baseline (Week 0, Day 1), Days 57, 113 \& 197 was conducted on first spot. Percent change from baseline at specified time points in TEWL AUC (first spot) in AD participants were reported in this OM.

Time frame:
Baseline, Days 57, 113 and 197
Reported as:
Mean · percent change
Percent Change From Baseline in AUC of TEWL on Non-lesional Skin in AD Participants at Days 57, 113 and 197
percent changeAtopic Dermatitis Participants
Day 57-21.7570 ± 29.1137
Day 113-10.8940 ± 50.7679
Day 197-28.6897 ± 26.0253
SecondaryAbsolute Change From Baseline in AUC of TEWL on Non-lesional Skin in AD Participants at Days 57, 113 and 197

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum to characterize SBF. TEWL combined with STS measures SBF. TEWL AUC done over defined number of STS used to reflect the overall integrity of stratum corneum. Non-LS areas for TEWL assessment and STS were identified at baseline(predefined skin area). Within predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10,15 and 20 STS on pre-defined non-LS areas at specified time points. TEWL AUC was a composite measure before and after 5, 10, 15 and 20 STS at each specified time point. AUC of TEWL: calculated for each visit using trapezoidal method. STS assessment at baseline(Week 0, Day 1), Days 57, 113 and 197 was conducted on first spot. Absolute change from baseline at specified time points in TEWL AUC (first spot) in AD participants reported in this OM.

Time frame:
Baseline, Days 57, 113 and 197
Reported as:
Mean · nsts*grams per square meter per hour
Absolute Change From Baseline in AUC of TEWL on Non-lesional Skin in AD Participants at Days 57, 113 and 197
nsts*grams per square meter per hourAtopic Dermatitis Participants
Day 57-281.9579 ± 342.1271
Day 113-217.7544 ± 462.0173
Day 197-367.5469 ± 340.1948
SecondaryPercent Change From Baseline in AUC of TEWL on Normal Skin in Healthy Volunteers at Days 57, 113 and 197

TEWL: noninvasive in vivo measurement of water loss across stratum corneum to characterize SBF. TEWL combined with STS measures SBF. TEWL AUC done over a defined number of STS used to reflect the overall integrity of the stratum corneum. Normal skin areas for TEWL assessment \& STS were identified at baseline(predefined skin area). Within predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL measured prior to STS \& after 5, 10,15 \& 20 STS on pre-defined normal skin areas at specified time points. TEWL AUC: composite measure before \& after 5, 10, 15\& 20 STS at each specified time point. AUC of TEWL: calculated for each visit using trapezoidal method. STS assessment at baseline (Week 0, Day 1), Days 57, 113 \& 197 conducted on first spot. Percent Change from baseline at specified time points in TEWL AUC (first spot) in healthy volunteers reported in this OM.

Time frame:
Baseline, Days 57, 113 and 197
Reported as:
Mean · percent change
Percent Change From Baseline in AUC of TEWL on Normal Skin in Healthy Volunteers at Days 57, 113 and 197
percent changeHealthy Volunteers
Day 573.2794 ± 15.6493
Day 1133.4753 ± 30.2504
Day 197-10.1582 ± 18.4753
SecondaryAbsolute Change From Baseline in AUC of TEWL on Normal Skin in Healthy Volunteers at Days 57, 113 and 197

TEWL: noninvasive in vivo measurement of water loss across stratum corneum to characterize SBF. TEWL combined with STS measures SBF. TEWL AUC done over defined number of STS used to reflect the overall integrity of stratum corneum. Normal skin areas for TEWL assessment and STS identified at baseline(predefined skin area). Within predefined Normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL measured prior to STS and after 5, 10,15 and 20 STS on pre-defined Normal skin areas at specified time points. TEWL AUC was a composite measure before and after 5, 10,15 and 20 STS at each specified time point. AUC of TEWL: calculated for each visit using trapezoidal method. STS assessment at baseline (Week 0, Day 1), Days 57, 113 and 197 conducted on first spot. Percent change from baseline at specified time points in TEWL AUC (first spot) in healthy volunteers reported in this OM.

Time frame:
Baseline, Days 57, 113 and 197
Reported as:
Mean · nsts*grams per square meter per hour
Absolute Change From Baseline in AUC of TEWL on Normal Skin in Healthy Volunteers at Days 57, 113 and 197
nsts*grams per square meter per hourHealthy Volunteers
Day 5716.8563 ± 70.4582
Day 1132.5568 ± 197.8379
Day 197-72.9050 ± 108.8230
SecondaryPercent Change From Baseline in TEWL After 5, 10, 15 and 20 STS on Lesional Skin in AD Participants at Days 57, 113 and 197

TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of skin are peeled away using adhesive discs. LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL: measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. STS assessment at baseline (Week 0, Day 1), Day 57, 113 and 197 were conducted on first spot. Percent change from baseline at specified time points in TEWL after STS on LS (first spot) in AD participant were reported in this OM.

Time frame:
Baseline, Days 57, 113 and 197
Reported as:
Mean · percent change
Percent Change From Baseline in TEWL After 5, 10, 15 and 20 STS on Lesional Skin in AD Participants at Days 57, 113 and 197
percent changeAtopic Dermatitis Participants
After 5 STS: Day 57-42.2019 ± 22.5314
After 5 STS: Day 113-38.5633 ± 27.1211
After 5 STS: Day 197-36.4601 ± 47.5902
After 10 STS: Day 57-40.4595 ± 27.4572
After 10 STS: Day 113-34.7741 ± 31.0541
After 10 STS: Day 197-39.9440 ± 29.2084
After 15 STS: Day 57-41.6561 ± 24.0960
After 15 STS: Day 113-33.3119 ± 32.7125
After 15 STS: Day 197-38.4286 ± 27.0978
After 20 STS: Day 57-34.8297 ± 23.0520
After 20 STS: Day 113-33.1336 ± 28.1613
After 20 STS: Day 197-35.6561 ± 23.0987
SecondaryAbsolute Change From Baseline in TEWL After 5, 10, 15 and 20 STS on Lesional Skin in AD Participants at Days 57, 113 and 197

TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of skin are peeled away using adhesive discs. LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within predefined LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL: measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. STS assessment at baseline (Week 0, Day 1), Day 57, 113 and 197 was conducted on first spot. Absolute change from baseline at specified time points in TEWL after STS on LS (first spot) in AD participants were reported in this OM.

Time frame:
Baseline, Days 57, 113 and 197
Reported as:
Mean · grams per square meter per hour
Absolute Change From Baseline in TEWL After 5, 10, 15 and 20 STS on Lesional Skin in AD Participants at Days 57, 113 and 197
grams per square meter per hourAtopic Dermatitis Participants
After 5 STS: Day 57-31.3795 ± 25.4943
After 5 STS: Day 113-31.1761 ± 31.3420
After 5 STS: Day 197-33.5753 ± 40.1857
After 10 STS: Day 57-36.4267 ± 31.1758
After 10 STS: Day 113-33.1024 ± 36.2286
After 10 STS: Day 197-35.8254 ± 33.3362
After 15 STS: Day 57-37.9779 ± 23.3049
After 15 STS: Day 113-33.4028 ± 31.1957
After 15 STS: Day 197-36.0843 ± 27.5612
After 20 STS: Day 57-35.0726 ± 23.5765
After 20 STS: Day 113-35.6671 ± 31.2267
After 20 STS: Day 197-34.5257 ± 23.9001
SecondaryPercent Change From Baseline in TEWL After 5, 10, 15 and 20 STS on Non-lesional Skin in AD Participants at Days 57, 113 and 197

TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, uppermost layers of skin are peeled away using adhesive discs. Non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL: measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at baseline (Week 0, Day 1), Day 57, 113and 197 was conducted on first spot. Percent change from baseline at specified time points in TEWL after STS on non-LS (first spot) in AD participants were reported in this OM.

Time frame:
Baseline, Days 57, 113 and 197
Reported as:
Mean · percent change
Percent Change From Baseline in TEWL After 5, 10, 15 and 20 STS on Non-lesional Skin in AD Participants at Days 57, 113 and 197
percent changeAtopic Dermatitis Participants
After 5 STS: Day 57-24.8218 ± 31.4633
After 5 STS: Day 113-4.8842 ± 70.5670
After 5 STS: Day 197-29.7635 ± 44.0691
After 10 STS: Day 57-20.3640 ± 43.5318
After 10 STS: Day 113-3.8193 ± 74.6263
After 10 STS: Day 197-29.6888 ± 38.9536
After 15 STS: Day 57-18.4348 ± 33.3647
After 15 STS: Day 113-7.6067 ± 54.7945
After 15 STS: Day 197-27.2268 ± 25.1580
After 20 STS: Day 57-19.2584 ± 30.1343
After 20 STS: Day 113-6.1452 ± 67.9496
After 20 STS: Day 197-22.3311 ± 23.0908
SecondarySecondary: Absolute Change From Baseline in TEWL After 5, 10, 15 and 20 STS on Non-lesional Skin in AD Participants at Days 57, 113 and 197

TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, uppermost layers of skin are peeled away using adhesive discs. Non-LS areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within predefined non-LS areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL: measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at baseline (Week 0, Day 1), Day 57, 113 and 197 was conducted on the first spot. Absolute change from baseline at specified time points in TEWL after STS on non-LS (first spot) in AD participants were reported in this OM.

Time frame:
Baseline, Days 57, 113 and 197
Reported as:
Mean · grams per square meter per hour
Secondary: Absolute Change From Baseline in TEWL After 5, 10, 15 and 20 STS on Non-lesional Skin in AD Participants at Days 57, 113 and 197
grams per square meter per hourAtopic Dermatitis Participants
After 5 STS: Day 57-11.8526 ± 12.6180
After 5 STS: Day 113-9.0771 ± 21.3022
After 5 STS: Day 197-15.8375 ± 18.0369
After 10 STS: Day 57-15.0005 ± 20.1721
After 10 STS: Day 113-10.9488 ± 31.1300
After 10 STS: Day 197-21.2825 ± 23.2998
After 15 STS: Day 57-16.1047 ± 26.4807
After 15 STS: Day 113-12.6576 ± 30.0412
After 15 STS: Day 197-21.9006 ± 19.2885
After 20 STS: Day 57-18.5800 ± 30.3574
After 20 STS: Day 113-13.6682 ± 33.3065
After 20 STS: Day 197-20.0575 ± 16.1537
SecondaryPercent Change From Baseline in TEWL After 5, 10, 15 and 20 STS on Normal Skin in Healthy Volunteers at Days 57, 113 and 197

TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, uppermost layers of skin are peeled away using adhesive discs. Normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at baseline (Week 0, Day 1), Day 57, 113 and 197 was conducted on first spot. Percent change from baseline at specified time points in TEWL after STS on normal skin (first spot) in healthy volunteers were reported in this OM.

Time frame:
Baseline, Days 57, 113 and 197
Reported as:
Mean · percent change
Percent Change From Baseline in TEWL After 5, 10, 15 and 20 STS on Normal Skin in Healthy Volunteers at Days 57, 113 and 197
percent changeHealthy Volunteers
After 5 STS: Day 574.9595 ± 16.0950
After 5 STS: Day 1131.4464 ± 26.7257
After 5 STS: Day 197-1.6729 ± 25.2293
After 10 STS: Day 574.0996 ± 20.4647
After 10 STS: Day 1130.7091 ± 25.0615
After 10 STS: Day 197-7.4475 ± 19.7215
After 15 STS: Day 573.2339 ± 20.9086
After 15 STS: Day 1134.5364 ± 42.7525
After 15 STS: Day 197-14.0103 ± 18.5552
After 20 STS: Day 574.3494 ± 27.5527
After 20 STS: Day 11313.2578 ± 64.3880
After 20 STS: Day 197-18.0480 ± 22.6193
SecondaryAbsolute Change From Baseline in TEWL After 5, 10, 15 and 20 STS on Normal Skin in Healthy Volunteers at Days 57, 113 and 197

TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, uppermost layers of skin are peeled away using adhesive discs. Normal skin areas for TEWL assessment and STS were identified at baseline (predefined skin area). Within predefined normal skin areas, 3 closely adjacent non-overlapping spots were identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at baseline (Week 0, Day 1), Day 57, 113 and 197 were conducted on first spot. Absolute change from baseline at specified time points in TEWL after STS on normal skin (first spot) in healthy volunteers were reported in this OM.

Time frame:
Baseline, Days 57, 113 and 197
Reported as:
Mean · grams per square meter per hour
Absolute Change From Baseline in TEWL After 5, 10, 15 and 20 STS on Normal Skin in Healthy Volunteers at Days 57, 113 and 197
grams per square meter per hourHealthy Volunteers
After 5 STS: Day 570.5642 ± 3.3355
After 5 STS: Day 113-1.0255 ± 4.3657
After 5 STS: Day 197-1.5627 ± 5.2934
After 10 STS: Day 570.2825 ± 4.5142
After 10 STS: Day 113-1.3482 ± 6.6778
After 10 STS: Day 197-3.0880 ± 5.2754
After 15 STS: Day 570.4750 ± 6.4442
After 15 STS: Day 1130.1082 ± 17.5865
After 15 STS: Day 197-5.8847 ± 8.1968
After 20 STS: Day 573.4683 ± 9.8235
After 20 STS: Day 1135.9327 ± 32.0123
After 20 STS: Day 197-7.4760 ± 9.3514

Adverse events

Collected over For AD participants: from first dose (i.e., Day 1) of IMP administration up to end of treatment visit (i.e., Day 113). For healthy volunteers: from signature of consent form to end of study (i.e., up to Day 197). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Healthy Volunteers0/18 (0%)0/18 (0%)6/18 (33.3%)
Atopic Dermatitis Participant0/23 (0%)0/23 (0%)21/23 (91.3%)
Most frequent other events
Showing 10 of 40
Most frequent other events
EventHealthy VolunteersAtopic Dermatitis Participant
Dermatitis AtopicSkin and subcutaneous tissue disorders0/189/23
Medical Device Site HaemorrhageGeneral disorders0/186/23
Upper Respiratory Tract InfectionInfections and infestations0/184/23
HeadacheNervous system disorders1/183/23
UrticariaSkin and subcutaneous tissue disorders0/183/23
PyrexiaGeneral disorders2/180/23
Eye PruritusEye disorders0/182/23
Covid-19Infections and infestations1/181/23
Skin Bacterial InfectionInfections and infestations1/180/23
LymphadenopathyBlood and lymphatic system disorders1/180/23

Baseline characteristics

Analysis was performed on modified intent-to-treat (mITT) population which included all enrolled AD participants who received at least 1 dose of investigational medicinal product (IMP) and all enrolled healthy volunteers who had at least 1 TEWL/STS assessment performed, irrespective of compliance with protocol and procedures. If prohibited therapies used for AD, only visits prior to rescue treatment were considered.

Age, Continuous
Age, Continuous(years)Healthy VolunteersAtopic Dermatitis ParticipantsTotal
Mean8.2 ± 1.87.8 ± 1.68.0 ± 1.7
Sex: Female, Male
Sex: Female, Male(Participants)Healthy VolunteersAtopic Dermatitis ParticipantsTotal
Female8816
Male101525
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Healthy VolunteersAtopic Dermatitis ParticipantsTotal
American Indian or Alaska Native000
Asian639
Native Hawaiian or Other Pacific Islander000
Black or African American224
White91625
More than one race011
Unknown or Not Reported112
08

Study locations

3 sites
  • Investigational Site Number :8400002
    Los Angeles, California 90027, United States
  • Investigational Site Number :8400001
    Denver, Colorado 80206, United States
  • Investigational Site Number :8260001
    Sheffield, S10 2TH, United Kingdom
09

References and documents

Publications

  • Cork MJ, Ong PY, Danby SG, Byers RA, Matcher SJ, Katibi OS, Brown K, Andrew PV, Pinnock A, Poyner A, Johnson L, Gormley S, Hyde A, Ramirez-Gama M, Garcia S, Taylor PA, Bologna G, Praestgaard AH, Zahn J, Zhang A, Leung DYM. Dupilumab treatment restores epithelial barrier in nonlesional and lesional skin in children with atopic dermatitis. Ann Allergy Asthma Immunol. 2026 May;136(5):558-564.e3. doi: 10.1016/j.anai.2026.01.008. Epub 2026 Jan 27. PubMed 41611123 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Sep 2022, 18 months.

Results were first posted in Oct 2023, 1 year 1 month after primary completion.

Of 45 phase 4 interventional studies under Dermatitis, Atopic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2021
First posted
Jan 22, 2021
StartActual
Feb 19, 2021
Primary completionActual
Sep 7, 2022
CompletionActual
Nov 30, 2022
Results first posted
Oct 17, 2023
Last update
Sep 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04718870
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jan 22, 2021
Start date
Feb 19, 2021
Primary completion
Sep 7, 2022
Completion
Nov 30, 2022
Results posted
Oct 17, 2023
Last update
Sep 15, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion